ReviewNature reviews. Rheumatology2010
Biological therapy for lupus nephritis-tribulations and trials.
Review in Nature reviews. Rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Clinical research progress of novel biologics for the treatment of lupus nephritis.Clinical and experimental medicine · 2023Review
- Distinct pathogenic roles for resident and monocyte-derived macrophages in lupus nephritis.JCI insight · 2022Article
- Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?Nature reviews. Rheumatology · 2017Review
- The flavors of plasma cells.Oncotarget · 2015Article
- Treatment of severe lupus nephritis: the new horizon.Nature reviews. Nephrology · 2015Review
- The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.BMC musculoskeletal disorders · 2014Article
- Lipid anti-lipid antibody responses correlate with disease activity in systemic lupus erythematosus.PloS one · 2013Article
- Belimumab.Nature reviews. Drug discovery · 2011Article
- Murine models of systemic lupus erythematosus.Journal of biomedicine & biotechnology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several new targeted biologic agents for treating lupus nephritis are on the horizon; however, it is important to determine the circumstances in which they should be used, and how to optimally combine these agents with current or other new therapies. Conventional immunosuppressive therapy has transformed survival in lupus nephritis, but its use is associated with considerable toxic effects and suboptimal efficacy. There is a clear need for new therapeutic agents that overcome these issues, and biologic agents offer exciting opportunities. B cells, T cells, cytokines and complement are potential targets for these therapies. It is anticipated that the role of B-cell depletion in lupus nephritis will be clarified and that other biologic agents will be developed. The complexities of clinical trials in lupus nephritis have impeded the demonstration of the efficacy of new agents, but if these difficulties can be overcome, there is a real chance that outcomes in lupus nephritis will improve.
Indexed as
Identifiers
20647994What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.